SCHEMBL2804123

SCHEMBL2804123

COCc1cc(-c2nc(-c3ccc(C(=O)O)c(F)c3)no2)ccc1-c1ccccc1F

nearest known ligand 0.80

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 9/20 0.80
S1PR3 Q99500 2/20 0.80
MAOA P21397 1/20 0.50
BLVRB P30043 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
NPC1 O15118 5/20 0.49
RAB9A P51151 5/20 0.49
RARA P10276 4/20 0.47
RARB P10826 4/20 0.47
RARG P13631 4/20 0.47
TP53 P04637 1/20 0.45
MAPT P10636 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2773884 0.95 S1PR1 (0.81) S1PR1S1PR3MAOABLVRBHDAC6
SCHEMBL9928648 0.93 S1PR1 (0.79) S1PR1S1PR3MAOABLVRBHDAC6
SCHEMBL406882 0.93 S1PR1 (0.93) S1PR1S1PR3RARARARBRARG
SCHEMBL2772469 0.93 S1PR1 (0.69) S1PR1S1PR3MAOABLVRBHDAC6
SCHEMBL2774344 0.92 S1PR1 (0.76) S1PR1S1PR3MAOABLVRBHDAC6
SCHEMBL2772342 0.92 S1PR1 (0.76) S1PR1S1PR3NPC1RAB9ARARA
SCHEMBL2772698 0.90 S1PR1 (0.74) S1PR1S1PR3RARARARBRARG
SCHEMBL2775468 0.90 S1PR1 (0.70) S1PR1S1PR3MAOABLVRBHDAC6
SCHEMBL2773624 0.89 S1PR1 (0.73) S1PR1S1PR3NPC1RAB9ARARA
SCHEMBL2803542 0.89 S1PR1 (0.81) S1PR1S1PR3MAOABLVRBHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2193125-B1 OXADIAZOLE DERIVATIVES MERCK SERONO SA (CH) 2017-01-11 EP disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-8202865-B2 Oxadiazole derivatives MERCK SERONO SA (CH) 2012-06-19 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
US-20100240658-A1 Oxadiazole Derivatives MERCK SERONO SA (CH) 2010-09-23 US disclosed
EP-2193125-A2 OXADIAZOLE DERIVATIVES Merck Serono S.A. (CH) 2010-06-09 EP disclosed
WO-2009043889-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2009-04-09 WO disclosed
WO-2009043889-A2 OXADIAZOLE DERIVATIVES MERCK SERONO S.A. (CH) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240658-A1 Oxadiazole Derivatives OXA1L, RO60, NQO2 S1PR1 483/4885S1PR3 335/4885MAOA 2543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.